In our recent study on the efficacy of three EGFR‐TKIs in patients with EGFR‐mutation‐positive advanced NSCLC,14 we found that patients who received afatinib had longer PFS and marginally longer OS than patients who received gefitinib. Here, EGFR is linked to non-small cell lung carcinoma.